Mediar Therapeutics
Clinical trials sponsored by Mediar Therapeutics, explained in plain language.
-
New hope for rare scleroderma: experimental drug MTX-474 enters phase 2 trial
Disease control Recruiting nowThis study tests whether the experimental drug MTX-474 can safely reduce skin thickening in people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin to harden and can damage internal organs. About 85 adults with early-stage disease will receive…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 17, 2026 07:06 UTC
-
New hope for lung scarring: experimental drug MTX-463 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called MTX-463 in 164 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants will receive either the drug or a placebo to see if MTX-463 can slow the decline in lung functio…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC